Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of BioNTech's BNT-323?
BNT-323 is a monoclonal antibody conjugated commercialized by BioNTech, with a leading Phase III program in Metastatic Breast Cancer. According...